Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for hereditary angioedema with normal C1inh not related to F12 or PLG variant has been reported in the published literature.
No clinical trials have been registered for hereditary angioedema with normal C1inh not related to F12 or PLG variant.
83 publications have been identified in PubMed for hereditary angioedema with normal C1inh not related to F12 or PLG variant. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (24%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:35 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
20 |
24% |
Disease patterns and progression | 12 | 15% |
Laboratory research | 9 | 11% |
Testing and diagnosis research | 8 | 10% |
Clinical study results | 4 | 5% |
New treatment approaches | 2 | 2% |
Thambiraja M (2026). [PMID: 41840107](https://pubmed.ncbi.nlm.nih.gov/41840107/). *Sci Rep*. [Basic Science / Preclinical]
Casanova M (2026). [PMID: 41723522](https://pubmed.ncbi.nlm.nih.gov/41723522/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Sajjad A (2026). [PMID: 41992156](https://pubmed.ncbi.nlm.nih.gov/41992156/). *BMC Nephrol*. [Case Report / Case Series]
Magerl M (2026). [PMID: 41788693](https://pubmed.ncbi.nlm.nih.gov/41788693/). *Allergol Select*. [Epidemiology / Natural History]
Busse P (2026). [PMID: 41698689](https://pubmed.ncbi.nlm.nih.gov/41698689/). *Allergy Asthma Proc*. [Review / Meta-Analysis]
Zhang B (2026). [PMID: 42125081](https://pubmed.ncbi.nlm.nih.gov/42125081/). *Front Med (Lausanne)*. [Case Report / Case Series]
Lu YF (2026). [PMID: 41663186](https://pubmed.ncbi.nlm.nih.gov/41663186/). *Zhonghua Xue Ye Xue Za Zhi*. [Case Report / Case Series]
Banerji A (2026). [PMID: 41794053](https://pubmed.ncbi.nlm.nih.gov/41794053/). *J Allergy Clin Immunol*. [Clinical Trial Publication]
Xu Y (2026). [PMID: 40209692](https://pubmed.ncbi.nlm.nih.gov/40209692/). *Int Arch Allergy Immunol*. [Review / Meta-Analysis]
Jones D (2026). [PMID: 41533199](https://pubmed.ncbi.nlm.nih.gov/41533199/). *Clin Exp Med*. [Epidemiology / Natural History]
AI-curated news mentioning hereditary angioedema with normal C1inh not related to F12 or PLG variant
Updated Feb 6, 2026
BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal to enhance its portfolio with a long-acting preventive therapy for hereditary angioedema. This acquisition reflects a strategic shift in venture firms' preferences as the biotech sector recovers.
Intellia is set to report Phase 3 trial results for a potential treatment for hereditary angioedema in the first half of 2026, amidst a backdrop of significant clinical trial activity in rare diseases. Despite recent challenges, including a study participant's death and program suspensions, the biotech sector is regaining momentum with key readouts expected across various conditions.